Vemurafenib-related cutaneous side effects ameliorated by acitretin

Journal of Drugs in Dermatology

Volumn 13, Issue 5, 2014, Pages 586-588

  Chon, Susan Y ^a   Sambrano, Brittany L ^b   Geddes, Elizabeth R ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN; VEMURAFENIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; KERATOLYTIC AGENT; SULFONAMIDE;

ACTINIC KERATOSIS; ADULT; ARTICLE; CASE REPORT; CHEMOPROPHYLAXIS; DRUG EFFICACY; FEMALE; HUMAN; HYPERKERATOSIS; KERATOACANTHOMA; METASTATIC MELANOMA; MIDDLE AGED; SKIN CARCINOMA; TREATMENT OUTCOME; VERRUCA VULGARIS; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; DISEASE COURSE; FOLLOW UP; MELANOMA; PATHOLOGY; PROCEDURES; SKIN NEOPLASMS;

ACITRETIN; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOPREVENTION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; KERATOLYTIC AGENTS; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84900536434     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. http://www.cancer.gov/cancertopics/druginfo/fda-vemurafenib
2. Sosman JA, Kim KB, Schuchter L. Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey R Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAFV600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb. 23:366(8):707-14. PubMed PMID: 22356324.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B. Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA: BRIM-3 Study Group. Improvedsurvival with vemurafenib in melanoma with BRAF V600E mutation. N EnglJ Med. 2011 Jun. 30:364(26):2507-16
4. Huang V, Hepper D, Anadkat M, Cornelius L. CutaneousToxic Effects Associated With Vemurafenib and Inhibition of the BRAF Pathway. Arch Dermatol. 2012 Mar. 19. lEpub ahead of print] PubMed PMID: 22431713.
5. Su F, Viros A, Milagre C et al. RAS mutations in cutaenous squamouscell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-15.
6. Flaherty KT, Infante JR. Daud A, Gonzalez R, Kefford RF Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun R, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov; 367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep. 29. PubMed PMID: 23020132.
7. Kadakia KC, Barton DL, Loprinzi CL, Sloan JA, Otley CC, Diekmann BB, Novotny PJ, Alberts SR, Limburg PJ, Pittelkow MR. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 9692511. Cancer. 2012 Apr. 15; 118(8):2128-37. doi: 10.1002/cncr.26374. Epub 2011 Aug. 31. PubMed PMID: 21882176; PubMed Central PMCID: PMC3365547.
8. Hardin J, Mydlarski PR. Systemic retinoids: chemoprevention of skin cancer in transplant recipients. Skin Therapy Lett. 2010 Jul-Aug; 15(7):1-4. Review. PubMed PMID: 20700551.